Significant itch relief and skin clearance1,2

Results from a Phase 3 study of atopic dermatitis patients 12+ years of age with uncontrolled moderate-to-severe hand and/or foot involvement (AD-HAFT)1,2

Itch relief
in ≈4x as many patients
52% DUPIXENT
VS
14% Placebo

patients who achieved ≥4-point improvement in hand
and foot Peak Pruritus NRS
at Week 16 in AD-HAFT
(P<0.0001; secondary endpoint)

Skin clearance (IGA
hand and foot 0 OR 1)
in >2x as many patients
40% DUPIXENT
VS
17% Placebo

patients who achieved clear or almost-clear skin (hand and
foot IGA 0 or 1)
at Week 16 in AD-HAFT (P=0.0030;
primary endpoint)

47%

of DUPIXENT patients achieved ≥75% improvement from baseline in hand lesion extent and severity (HECSI-75)a vs 22% with placebo at Week 16 in AD-HAFT (P=0.0028; secondary endpoint)1,2

Safety Profile

The safety profile in AD-HAFT was consistent with the safety profile from pivotal studies in adult and pediatric subjects 6 months of age and older with moderate-to-severe atopic dermatitis. The most common adverse reactions (incidence ≥1%) are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia.1,2


Trial Design

133 subjects aged 12 years and older in AD-HAFT (16 weeks) with atopic dermatitis with moderate-to-severe hand and/or foot involvement inadequately controlled with or intolerant to topical Rx therapies were randomized to DUPIXENT or placebo. Participants included subjects with both hand and foot involvement (n=71), foot-only involvement (n=4), and hand-only involvement (n=58). All DUPIXENT-treated adults and adolescents ≥60 kg received 300 mg Q2W after a 600 mg loading dose and adolescents <60 kg received 200 mg Q2W after a 400 mg loading dose. Patients had an IGA hand and foot score ≥3 on a scale of 0 to 4. At baseline, 72% had an IGA hand and foot score of 3 (moderate), 28% had an IGA hand and foot score of 4 (severe), mean hand and foot Peak Pruritus NRS was 7.1 on a scale of 0 to 10, and mean HECSI score was 46.8 on a scale of 0 to 360.1,2

Not an actual patient.

CONSIDER THE BURDEN
THAT
SMALL BSA INVOLVEMENT CAN HAVE2-5

ADULT PATIENT 1ACHIEVED A 3-POINT IMPROVEMENT
IN IGA hand and foot score

This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT. Scoring was designated by the treating physician. Because this patient was a real-world patient, other factors, including concomitant medication, may have influenced their treatment results, individual results may vary.

BASELINE: IGA HAND AND
FOOT 4 (severe)
WEEK 16: IGA HAND AND FOOT 1
(almost clear)

A clinical responder was defined as a patient achieving IGA hand and foot 0 or 1.1

EXPLORE SAFETY DATA FROM ADULT AND ADOLESCENT PIVOTAL TRIALS IN UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD)

Extensive Real-World
Experience IN AD

# 1

prescribed biologic by
dermatologists and allergists2,b,c

 
6

years since initial FDA
approval in AD in adults1,d

≈750,000

patients on
DUPIXENT therapy
worldwide
across 5 indications2,e,f

patients on
DUPIXENT therapy

worldwide across
5 indications2,e,f

AD, atopic dermatitis; BSA, body surface area; HECSI, Hand Eczema Severity Index; IGA, Investigator’s Global Assessment; NRS, numerical rating scale.

aHECSI is a clinical scale that combines severity of the clinical signs of hand eczema and the extent of skin involvement. The severity of 6 clinical signs of hand eczema in 5 areas of the hands is assessed on a scale of 0 to 3. The extent of lesions in each area of the hands is evaluated based on a percentage involvement of surface area and is given a value between 0 and 4.6

bIQVIA NBRx data as of July 2023.

cIQVIA NBRx data as of June 2023.

dFDA approved since 2017 for adults, 2019 for adolescents (aged 12-17 years), 2020 for children (aged 6-11 years), and 2022 for infants to preschoolers (aged 6 months to 5 years) with uncontrolled moderate-to-severe AD.

eThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈10% of this worldwide patient number. Data through August 2023.

f≈387,000 US AD patients have filled at least 1 DUPIXENT prescription based on IQVIA National Source of Business (NSOB) data as of June 2023.

One dosage regimen in adults1

18+ YEARS

One dosage
regimen in adults

Initial loading dose:

600 mg

2 x 300 mg


Weight-tiered dosage regimen in adolescents1,a

12 to 17 YEARS

≥60 kga

Initial loading dose:

600 mg

2 x 300 mg


<60 kg

Initial loading dose:

400 mg

2 x 200 mg

a60 kg is equal to 132 lb.

DOSING FOR DUPIXENT IN AD-HAFT WAS CONSISTENT WITH THE APPROVED DOSAGE FOR ATOPIC DERMATITIS IN THE PRESCRIBING INFORMATION1,2

Support can make all the difference. DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-to-one ongoing support, and more.

DUPIXENT MyWay
ENROLLMENT FORMS

English Enrollment Form
Spanish Enrollment Form